2.1 Acute Coronary Syndromes: STEMI, NSTEMI, and Unstable Angina
Key Takeaways
Use primary PCI when wire crossing is feasible within 120 minutes of ECG diagnosis. If not, assess early-presenting STEMI for prompt fibrinolysis, taking account of symptoms, contraindications and the product label, and arrange immediate transfer.
In inferior STEMI with hypotension, raised jugular venous pressure and clear lungs, check right-sided leads for RV involvement. Stop nitrate, assess filling and perfusion and avoid indiscriminate fluid loading while arranging urgent reperfusion.
In suspected NSTE-ACS, use the local rapid troponin algorithm. Acute MI requires troponin rise or fall with a value above the relevant 99th percentile and evidence of ischaemia. In suspected pericarditis, check for myocardial involvement, effusion and other high-risk findings.
Very high-risk NSTE-ACS needs immediate angiography. In high-risk NSTE-ACS, consider early angiography within 24 hours. Plan antithrombotics according to the invasive or fibrinolytic strategy and the bleeding risk.
Individualise secondary prevention. Twelve months of dual antiplatelet therapy is the default after ACS in suitable patients. Aim for LDL-C below 1.4 mmol/L and at least a 50% reduction, and use ventricular function and comorbidities to guide other therapy.
Acute coronary syndromes and myocardial infarction
Acute coronary syndromes (ACS) include STEMI, NSTEMI and unstable angina. A common mechanism is acute atherothrombosis. In plaque rupture, disruption of a fibrous cap exposes thrombogenic material. In plaque erosion, endothelial loss can trigger thrombosis without a deep cap rupture. Either process can activate platelets and coagulation. The ECG and clinical trajectory guide immediate treatment. They cannot establish the plaque mechanism.
Apply the 2026 Fifth Universal Definition
Acute myocardial injury means a rise or fall in cardiac troponin with at least one result above the sex-specific 99th percentile upper reference limit for the assay. To diagnose acute MI, identify acute myocardial injury with evidence of ischaemia, such as ischaemic symptoms, new ischaemic ECG changes or pathological Q waves, evidence of acute coronary pathology on imaging, or new ischaemic-pattern loss of viable myocardium or regional wall motion abnormality.
- Primary MI results from an acute coronary process, including atherothrombosis, coronary dissection, coronary embolism or vasospasm.
- Secondary MI results from an acute condition producing oxygen supply–demand imbalance. Under the Fifth Definition, confirming secondary MI requires objective evidence, such as ischaemia from obstructive coronary disease without an acute coronary culprit or a new ischaemic-pattern regional wall motion abnormality or loss of viable myocardium. Sepsis or tachycardia with a troponin rise alone does not establish secondary MI.
- Procedure-related MI occurs when an acute cardiac procedural complication produces injury and ischaemia. Interpret biomarkers, timing and other evidence together under the procedure-specific criteria.
Unstable angina is myocardial ischaemia without acute cardiomyocyte injury. An elevated troponin can coexist with another cause of chronic injury. In a patient with an ECG and symptoms indicating ongoing coronary occlusion, activate emergency reperfusion without waiting for troponin. Fifth Universal Definition of MI · ESC ACS guideline
Clinical presentation and ECG localisation
ACS can present with pressure, tightness or discomfort in the chest, arm, jaw, neck or epigastrium. Dyspnoea, diaphoresis, nausea, fatigue or collapse may accompany it or predominate. Consider ACS in older adults and people with diabetes who present without classic chest pain. Chest discomfort remains a common presentation in women. Interpret the whole clinical picture, and do not use relief with GTN to distinguish coronary from non-coronary pain.
12-Lead Electrocardiography: Lead Contiguity and Regional Localisation
A 12-lead ECG must be acquired and interpreted within 10 minutes of first medical contact (FMC). Contiguous leads are anatomically adjacent leads facing the same myocardial territory. In a compatible clinical setting, new J-point ST elevation in at least two contiguous leads supports acute coronary occlusion. The standard thresholds below apply in the absence of LV hypertrophy or bundle branch block:
- Leads V2–V3: (0.25 mV) in men years; (0.2 mV) in men years; (0.15 mV) in women of any age.
- All Other Leads: (0.1 mV) in men and women.
- Reciprocal Changes: Reciprocal depression supports regional ischaemia. Diffuse elevation with PR depression suggests pericarditis, but no single feature settles the differential. Repeat the ECG for persistent symptoms or evolving changes. Suspected ongoing occlusion with bundle branch block requires urgent assessment even if standard ST criteria cannot be applied.
| Myocardial Territory | Contiguous ECG Leads | Culprit Coronary Artery | Reciprocal Lead Changes | High-Yield Clinical Hazards |
|---|---|---|---|---|
| Anteroseptal | V1, V2 | Left Anterior Descending (LAD) | None | High incidence of bundle branch blocks, acute LV dysfunction |
| Anterior | V3, V4 | Left Anterior Descending (LAD) | II, III, aVF | Large infarct territory; risk of cardiogenic shock and apical mural thrombus |
| Anterolateral / Extensive Anterior | V1–V6, I, aVL | Proximal LAD or Left Main Stem | II, III, aVF | Massive anterior infarction, acute pulmonary oedema, free wall or septal rupture |
| High Lateral | I, aVL | Left Circumflex (LCx) or diagonal LAD | II, III, aVF | Subtle ST elevation easily overlooked on casual review |
| Inferior | II, III, aVF | RCA or LCx | I, aVL | Sinus bradycardia, Mobitz I block, complete heart block (nodal); check V4R |
| Posterior | V7, V8, V9 (ST elevation ) | LCx (obtuse marginal) or distal RCA | Horizontal ST depression, tall upright R waves (R/S > 1), upright T in V1–V3 | Record posterior leads when posterior occlusion is suspected |
| Right Ventricular (RV) | V3R, V4R (additional right-sided leads) | Proximal RCA | Accompanying inferior ST elevation | Check haemodynamics and avoid nitrate in RV infarction, especially with hypotension |
Right ventricular infarction and high-sensitivity troponin
In inferior STEMI, right ventricular involvement can cause hypotension with raised jugular venous pressure and clear lungs. A proximal right coronary occlusion is a typical cause. Poor RV output reduces LV filling and cardiac output. Look for right-sided ST elevation, particularly in V4R, and assess for bradycardia or AV block. The combination of shock and clear lungs can also occur with other emergencies.
Stop nitrates if hypotension or RV infarction is suspected. Reassess blood pressure, perfusion, ECG rhythm, jugular venous pressure and congestion, and activate urgent reperfusion. A small crystalloid challenge with reassessment can help when filling appears inadequate and there is no congestion. Repeated large boluses can overdistend the RV and worsen output, particularly when filling pressures are already high. Persistent shock needs urgent expert haemodynamic support and assessment for other causes. ESC ACS guideline · RV infarction haemodynamic study · 2026 cardiogenic shock clinical guide
Use the assay-specific pathway
For suspected non-ST-elevation ACS use the local high-sensitivity troponin 0/1-hour or 0/2-hour algorithm with the ECG and clinical assessment. These pathways use assay-specific absolute concentrations and changes. For example, the ESC Roche Elecsys hs-cTnT 0/1-hour pathway uses the following values in ng/L:
| Pathway | Example assay thresholds |
|---|---|
| Rule-out | Initial value below 5 if symptom onset was over three hours before sampling, or initial value below 12 with absolute one-hour change below 3. |
| Rule-in | Initial value at least 52 or an absolute one-hour change of at least 5. |
| Observe | Results between those decision groups require further assessment and repeat testing. |
A value from 9 to 11 ng/L has an absolute change of 2 ng/L and meets the two-sample rule-out threshold for that assay, assuming the protocol and clinical context apply. This does not clear a concerning ECG or ongoing symptoms. A rule-in result also needs clinical adjudication. Myocarditis, pulmonary embolism, heart failure, sepsis and tachyarrhythmias can cause acute injury. Stable elevations may reflect chronic injury, such as in chronic kidney or structural heart disease. ESC ACS guideline and assay table · Roche Elecsys example assay documentation
Initial ACS treatment and reperfusion
Monitor the patient, establish vascular access and obtain an ECG promptly. Give an aspirin loading dose, typically 300 mg orally in Irish acute care, unless contraindicated. Use additional antiplatelet and parenteral anticoagulant therapy according to the strategy, bleeding risk and current medicines. In ACS proceeding to PCI, prasugrel or ticagrelor is usually preferred to clopidogrel when suitable. Prior stroke or TIA contraindicates prasugrel. Age, weight and concomitant anticoagulation influence choice and dose. Routine P2Y12 pretreatment before the coronary anatomy is known is not recommended in NSTE-ACS when early angiography is planned.
GTN can relieve ischaemic symptoms if haemodynamics permit. Avoid it in hypotension, suspected RV infarction or recent PDE-5 inhibitor use. Titrate IV opioid for severe pain when indicated with monitoring. Opioids can delay absorption of oral P2Y12 inhibitors. Give supplemental oxygen for hypoxaemia. ESC uses an oxygen saturation below 90% in ACS. Use the appropriate controlled oxygen plan if the patient is at risk of hypercapnia.
STEMI reperfusion decisions
- Timely PCI: Arrange primary PCI if wire crossing is expected within 120 minutes of the ECG-based diagnosis. Activate the local Irish STEMI network and do not delay for biomarkers. Radial access is generally preferred for PCI when feasible.
- If timely PCI is unavailable: ESC recommends fibrinolysis for eligible patients within 12 hours of symptom onset, aiming for the bolus within 10 minutes of diagnosis, and immediate transfer to a PCI centre. The EU Metalyse STEMI indication for the 40 mg and 50 mg presentations is within six hours of symptom onset. Check the selected product and specialist pathway. Contraindications include previous haemorrhagic stroke, important recent bleeding or trauma and suspected aortic dissection. Check the full current contraindication list. If fibrinolysis is contraindicated, arrange the urgent PCI pathway.
- Adjuncts: A fibrinolysis strategy generally uses aspirin, clopidogrel and an appropriate anticoagulant. Check weight, age, renal function and dose adjustments. In older patients, discuss haemorrhage risk and the protocol for reduced-dose tenecteplase. Avoid applying STEMI dosing to stroke.
- After fibrinolysis: Transfer immediately, even if the pain and ECG improve. Arrange rescue PCI for failed reperfusion, such as less than 50% ST resolution at 60–90 minutes, or clinical instability or re-occlusion. After successful reperfusion, ESC recommends routine angiography 2–24 hours after the lytic bolus.
HSE community STEMI pathway · ESC ACS guideline · EMA Metalyse product information
NSTE-ACS risk and post-infarction prevention
In NSTE-ACS, use history, ECG, troponin and haemodynamic findings to determine risk. The GRACE score uses age, heart rate, systolic BP, creatinine, Killip class, cardiac arrest at presentation, ST deviation and cardiac biomarker elevation. Fibrinolysis is not a treatment for NSTEMI or unstable angina.
| NSTE-ACS setting | Coronary and antithrombotic plan |
|---|---|
| Very high risk | Arrange immediate invasive assessment for shock or instability, refractory or recurrent pain despite treatment, life-threatening arrhythmia, mechanical complication, acute HF due to ongoing ischaemia, or recurrent dynamic ECG changes, particularly intermittent ST elevation. |
| High risk | Consider angiography within 24 hours for confirmed NSTEMI under the ESC pathway, dynamic ST/T changes, transient ST elevation or GRACE above 140. Use an inpatient invasive strategy when indicated. |
| Lower suspicion or risk | Reassess the diagnosis, observe or repeat testing as indicated and choose selective testing based on symptoms and risk. A single GRACE threshold cannot establish low risk. |
| Anticoagulation | In immediate or early invasive care, unfractionated heparin is generally used, with alternatives per protocol. If early angiography is not anticipated, ESC prefers fondaparinux over enoxaparin in suitable patients. Give procedural UFH if a patient on fondaparinux proceeds to PCI. Check renal function, bleeding and concomitant anticoagulation. |
Secondary prevention
- Antithrombotics: Aspirin plus a P2Y12 inhibitor for 12 months is the default after ACS if suitable. Shorten or adjust treatment in selected patients according to bleeding and ischaemic risk, PCI details and an independent indication for oral anticoagulation.
- Lipids: Start a high-intensity statin unless unsuitable. Aim for LDL-C below 1.4 mmol/L and a reduction of at least 50% from baseline. Review response in 4–6 weeks. Use ezetimibe and further lipid lowering as needed.
- Ventricular function and comorbidity: Measure LVEF. ACE inhibition or an ARB when appropriate is particularly important with LV systolic dysfunction, HF, diabetes, hypertension or CKD. Use beta-blockade when indicated, particularly with reduced LVEF. In recent evidence for patients with LVEF at least 50% and no other indication, routine beta-blockade did not improve the main outcomes. Make an individual decision in other EF ranges. Use an MRA such as eplerenone after MI when LVEF is 40% or below with HF or diabetes and renal function and potassium allow. Check drug-specific limits and monitor renal function and potassium.
- Rehabilitation: Offer cardiac rehabilitation. Address smoking, activity, diet, risk factors and adherence, and agree follow-up. ESC ACS guideline · Randomised evidence for post-MI beta-blockade with normal LVEF
Arrange structured recovery after coronary revascularisation
The Irish integrated cardiac rehabilitation model treats acute coronary syndrome and coronary revascularisation, including bypass surgery, as priority groups. The programme combines supervised or supported activity, risk management, education and psychological support. Confirm referral at discharge and discuss barriers to participating. Assess new breathlessness, fever, increasing surgical wound pain or discharge, and palpitations with presyncope promptly after cardiac surgery. Stable wound and functional recovery can be reviewed through the agreed surgical, rehabilitation and primary care plan.
HSE Cardiac Rehabilitation Clinical Action Guide · HSE recovery after bypass surgery
Assess stable exertional symptoms
Chest pressure brought on reproducibly by exertion and relieved by rest suggests a chronic coronary syndrome. Establish the threshold, recent change, associated symptoms and cardiovascular risk factors. New prolonged rest symptoms, rapid worsening or signs of instability need assessment through the acute pathway. A resting ECG can be normal in a person with chronic coronary disease.
In a stable patient, use the clinical history, examination, resting ECG and relevant risk factors to guide further investigation through the local pathway. ESC 2024 recommends estimating the clinical likelihood of obstructive coronary disease. Coronary CT angiography is useful to exclude obstructive disease and detect plaque in suitable patients. Functional imaging can identify inducible ischaemia and help guide management. A very high likelihood, high event risk or severe symptoms despite treatment can justify invasive assessment. Persistent exertional symptoms may have coronary causes even when major obstructive stenoses are absent.
Treat cardiovascular risk factors and address symptoms. Select antianginal therapy according to heart rate, blood pressure, ventricular function, other conditions and medicines. Explain emergency symptoms and how to use any prescribed rescue treatment. Discuss revascularisation with the specialist team when symptoms or anatomy justify it.
ESC 2024 chronic coronary syndrome guideline
Choose the primary-prevention lipid pathway
Confirm the lipid profile and assess smoking, blood pressure, diabetes, kidney disease, medicines and family history. For an apparently healthy adult without established vascular disease or another condition requiring a specific risk assessment, the ESC/EAS approach uses SCORE2 at ages 40–69 and SCORE2-OP at ages 70–89. Use Ireland's moderate-risk country calibration. Discuss modifiable risks and weigh LDL-C, estimated risk, treatment benefit and patient preferences when agreeing a plan. The post-ACS LDL target applies to a different risk group.
Very high untreated LDL-C with a family history of early coronary disease or tendon xanthomas should prompt assessment for familial hypercholesterolaemia. Exclude relevant secondary causes such as hypothyroidism and assess against familial criteria. Arrange timely lipid-lowering care and specialist review when indicated, including a family-testing plan. A low short-term risk estimate in a younger adult does not reassure in suspected familial disease.
Markedly raised triglycerides require a separate assessment because of pancreatitis risk. ESC/EAS identifies levels above 10 mmol/L as requiring action to prevent pancreatitis. Check for abdominal pain and vomiting, which warrant urgent assessment for pancreatitis, and address causes such as alcohol, poorly controlled diabetes and relevant medicines. Seek prompt advice on treatment when the elevation is severe.
ESC/EAS 2025 lipid update · ESC prevention and country risk calibration · ESC/EAS familial disease and severe triglycerides
Recognise post-infarction complications
New shock, pulmonary oedema or a murmur in the days after MI warrants immediate echocardiography and senior cardiology and surgical assessment. Timing and auscultation guide the differential. A soft or absent murmur cannot exclude a major lesion.
- Septal rupture: An acute left-to-right shunt can cause biventricular failure, pulmonary oedema or shock. A harsh pansystolic murmur at the left sternal border and a thrill are useful clues. Colour Doppler shows the shunt. Discuss haemodynamic support and timing and mode of closure urgently with the heart team.
- Papillary muscle rupture: Sudden severe mitral regurgitation and pulmonary oedema or shock can follow inferior or lateral infarction. The posteromedial papillary muscle is vulnerable because it generally has a single arterial supply. The apical murmur may be soft. Assess urgently by echocardiography, with transoesophageal imaging if needed, and obtain surgical input.
- Free wall rupture: Suspect haemopericardium and tamponade in sudden circulatory collapse or PEA after infarction. A contained rupture can form a pseudoaneurysm. Arrange emergency specialist intervention.
- Post-infarction pericarditis: Early inflammation can cause pleuritic, positional pain and a rub. Later post-cardiac injury syndrome can include fever and pleural or pericardial effusion. Reassess for reinfarction or mechanical complications before attributing new symptoms to pericarditis. ESC favours aspirin for early post-MI pericarditis, with colchicine as appropriate. Consider bleeding, kidney function and interactions.
AHA mechanical complications statement · ESC 2025 pericarditis guideline
Assess a first episode of possible acute pericarditis
Sharp chest pain that worsens on inspiration or lying flat and improves leaning forward is suggestive. Take an ECG, assess troponin and inflammatory markers, and use echocardiography to assess effusion, ventricular function and haemodynamics. Consider acute coronary syndrome and other dangerous causes of chest pain before settling on the diagnosis. In the ESC 2025 framework, a compatible presentation with at least two additional criteria establishes definite pericarditis. Additional criteria include a rub, typical ECG findings such as diffuse ST elevation or PR depression, raised C-reactive protein, and new or worsening effusion or evidence of inflammation on cardiac MRI. Troponin elevation prompts assessment for myocardial involvement.
High-risk features such as fever above 38°C, gradual onset, large effusion, tamponade or associated myocarditis warrant hospital assessment. Haemodynamic compromise with possible tamponade requires emergency care. For a low-risk first episode after appropriate evaluation, the ESC uses aspirin or an NSAID at anti-inflammatory doses with gastroprotection, plus colchicine if suitable. Check renal function, bleeding risk and drug interactions before prescribing. Arrange early review and advise avoiding strenuous activity until clinical remission. Renew assessment if symptoms persist, recur or worsen. Post-infarction and recurrent disease need management tailored to the cause and available specialist advice.
ESC 2025 diagnostic and management framework · ESC diagnostic and risk tables
A 62-year-old man presents to the emergency department with 2 hours of crushing retrosternal chest pain. His 12-lead ECG demonstrates 3 mm ST-segment elevation in leads II, III, and aVF, with reciprocal ST depression in leads I and aVL. Following administration of sublingual glyceryl trinitrate, his blood pressure drops from 124/78 mmHg to 78/48 mmHg. Examination reveals a raised jugular venous pressure of 6 cm above the sternal angle and clear lung fields bilaterally. Right-sided ECG leads demonstrate 1.5 mm ST-segment elevation in lead V4R. While the team activates emergency reperfusion, what is the best immediate response to the hypotension?
Stop nitrates, assess RV filling and perfusion and give a small monitored crystalloid challenge only if there is evidence that filling is inadequate.
Administer an intravenous bolus of furosemide 40 mg and insert a urinary catheter
Start an intravenous infusion of labetalol to control sympathetic autonomic discharge
Increase the dose of sublingual glyceryl trinitrate to resolve persistent epicardial spasm
A 54-year-old woman presents to a rural community hospital in the West of Ireland with 45 minutes of central chest pressure and diaphoresis. An ECG recorded at 08:15 demonstrates 3.5 mm ST-segment elevation in leads V1 to V4. The local hospital does not have a cardiac catheterisation laboratory. The regional primary PCI centre is located 140 km away, and the national ambulance transfer coordinator confirms that the earliest anticipated time from diagnosis to catheterisation laboratory wire crossing is 165 minutes. The team confirms there is no contraindication to fibrinolysis and that the STEMI tenecteplase pathway applies. Her blood pressure is 135/84 mmHg. What is the most appropriate reperfusion strategy?
Transfer immediately for primary percutaneous coronary intervention despite the anticipated 165-minute delay
Administer weight-adjusted intravenous tenecteplase immediately and arrange emergency transfer to the PCI centre
Administer fondaparinux 2.5 mg subcutaneously and perform elective coronary angiography within 48 hours
Administer intravenous unfractionated heparin and repeat the 12-lead ECG in 60 minutes before deciding on reperfusion
A 68-year-old woman is recovering on the cardiac care unit 5 days following an extensive anterior STEMI treated with primary PCI to the proximal LAD. She suddenly develops acute breathlessness, orthopnoea, and agitation. Her blood pressure is 82/50 mmHg, heart rate is 115 bpm, and respiratory rate is 28 breaths/min. Auscultation reveals a new, harsh, pansystolic murmur heard loudest at the lower left sternal border accompanied by a palpable systolic thrill, along with diffuse bilateral pulmonary rales. Echocardiography is urgently requested. What is the most likely underlying diagnosis?
Acute left ventricular free wall rupture with cardiac tamponade
Posteromedial papillary muscle rupture with acute severe mitral regurgitation
Ventricular septal rupture with an acute left-to-right intracardiac shunt
Dressler syndrome with large inflammatory pericardial effusion
A patient describes four months of similar chest pressure when walking up a hill. It subsides within minutes of rest and has not recently changed. No pain is present now and the resting ECG is normal. What is the most appropriate plan?
Discontinue evaluation because the resting ECG is normal
Give fibrinolysis for stable effort-related discomfort
Use serial troponins alone as the complete work-up for chronic symptoms
Assess clinical likelihood and cardiovascular risks and arrange suitable investigation through the stable chest pain pathway
A 42-year-old with no known vascular disease has untreated LDL-C of 6.3 mmol/L on repeat testing. Her father had a myocardial infarction at 44 and she has Achilles tendon xanthomas. Triglycerides are 1.2 mmol/L. What is the most appropriate approach?
Defer treatment if a short-term risk calculator estimates low risk
Assess for familial hypercholesterolaemia, check for secondary causes and arrange lipid management and family assessment
Use an acute pancreatitis pathway for severe hypertriglyceridaemia
Start dual antiplatelet treatment because this profile confirms acute coronary syndrome
After an acute chest pain assessment, a stable 34-year-old has a first episode of positional pleuritic pain, a friction rub, widespread PR depression, and raised CRP. Troponin is normal, echocardiography shows no effusion or dysfunction, and no high-risk findings or treatment contraindications are identified. What initial treatment fits the ESC approach?
High-dose corticosteroids as the default first treatment
An appropriate anti-inflammatory aspirin or NSAID regimen with gastroprotection plus colchicine, and early clinical review
Immediate pericardial drainage despite no effusion
Dual antiplatelet therapy to treat the inflammation
Sections you finish are checked off in the contents.